Management of Epistaxis in Warfarin-Treated APS Patient with INR 1.9
Do NOT stop warfarin or reverse anticoagulation—initiate first-line local control measures immediately, as the INR of 1.9 is subtherapeutic and stopping warfarin poses significant thrombotic risk in this high-risk APS patient. 1
Immediate Management Approach
Step 1: Assess Bleeding Severity
Determine if this is life-threatening bleeding by evaluating:
- Hemodynamic instability (hypotension, tachycardia)
- Posterior epistaxis
- Hemoglobin drop ≥2 g/dL or transfusion requirement of ≥2 units RBCs 1
In this case with simple nosebleeds and INR 1.9, this is NON-SEVERE bleeding.
Step 2: First-Line Local Control (Do This First)
Before considering any anticoagulation changes, implement these measures 1:
- Firm sustained nasal compression for 10-15 minutes
- Topical vasoconstrictors (oxymetazoline spray or cocaine-soaked pledgets)
- Anterior rhinoscopy after clot removal to identify bleeding site
- Nasal cautery (silver nitrate or electrocautery) if bleeding site identified—anesthetize first and limit to active bleeding site only
- Nasal packing if above measures fail—use resorbable packing given anticoagulation status 1
Step 3: Anticoagulation Management
Critical Point: The INR of 1.9 is BELOW the therapeutic target for APS (target INR 2.5, range 2.0-3.0) 2. This patient is actually under-anticoagulated.
Do the following 1:
- Do NOT give the next scheduled warfarin dose while actively bleeding
- Do NOT reverse anticoagulation with vitamin K, FFP, or PCC for non-severe bleeding
- Do NOT withhold warfarin beyond the acute bleeding episode
The 2020 AAO-HNS guidelines explicitly state that reversal agents and withholding medications increase thrombotic risk and should be avoided unless bleeding is life-threatening 1. For APS patients, this risk is particularly high—these patients require lifelong anticoagulation due to significant recurrent thrombosis risk 3.
Step 4: Once Bleeding Controlled
Resume warfarin immediately once epistaxis is controlled with local measures 4. Evidence shows warfarin can be safely continued in epistaxis patients when INR is within therapeutic range, and your patient is actually subtherapeutic 4.
Adjust warfarin dose upward to achieve target INR 2.5 (range 2.0-3.0) for APS 2. The current INR of 1.9 places this patient at risk for thrombotic complications.
Step 5: Coordinate Care
Consult with the hematology/rheumatology team managing the APS regarding:
- Optimal timing to resume therapeutic anticoagulation
- Whether bridging with LMWH is needed if warfarin must be held longer
- Risk stratification (triple-positive APS patients have highest thrombotic risk) 5
Key Pitfalls to Avoid
Do NOT routinely stop warfarin in all epistaxis patients—this outdated practice increases morbidity from thrombotic events 6, 4
Do NOT use reversal agents (vitamin K, FFP, 4-factor PCC) for non-severe bleeding—these expose patients to unnecessary risks and are reserved for life-threatening hemorrhage only 1
Do NOT forget that APS patients are at extremely high risk for recurrent thrombosis—the benefit-harm assessment strongly favors maintaining anticoagulation 1, 7
Do NOT assume the epistaxis is solely due to warfarin—check for other causes (trauma, hypertension, nasal pathology) 1
Evidence Quality Note
The 2020 AAO-HNS Clinical Practice Guideline provides Grade C evidence (observational studies and expert opinion) but with high confidence that first-line local measures should precede any anticoagulation reversal 1. This recommendation prioritizes avoiding thrombotic complications (which can be fatal or permanently disabling in APS) over the inconvenience of persistent epistaxis, which is almost always controllable with proper local measures.
The warfarin FDA label confirms target INR 2.0-3.0 for recurrent systemic embolism and thrombophilic conditions like APS 2, making the current INR of 1.9 inadequate for stroke/thrombosis prevention.